Arginine

BLOOD AND BLOOD FORMING ORGANS

Key facts

Arginine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1973. DrugCentral lists 2 molecular targets, including NOS2 and GPRC6A. Recorded indications include Diagnostic Test for Growth Hormone Secretion and Renal radiation exposure from Lutetium (177Lu) oxodotreotide.

• Approval status: ofp (first approved 1973 by the FDA).
• Molecular targets: NOS2 and GPRC6A (2 listed in DrugCentral).
• Indications: Diagnostic Test for Growth Hormone Secretion and Renal radiation exposure from Lutetium (177Lu) oxodotreotide.
• ATC code: B05XB01 (Amino acids).
• Molecular formula: C6H14N4O2; molecular weight 174.20 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Diagnostic Test for Growth Hormone Secretion
• Renal radiation exposure from Lutetium (177Lu) oxodotreotide

Contraindications (21)

• Allergic Reactions
• Classical phenylketonuria
• Constipation
• Dehydration
• End stage renal disease
• Hb SS disease
• Heart disease
• Humoral hypercalcemia of malignancy
• Hypercalcemia
• Hypercalciuria
• Hyperkalemia
• Hyperparathyroidism
• Kidney disease
• Kidney stone
• Metabolic acidosis
• Myocardial infarction in recovery phase
• Osteolysis
• Poisoning by digitalis glycoside
• Renal tubular acidosis
• Sarcoidosis
• Ventricular fibrillation

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Nitric oxide synthase, inducible	NOS2	unknown	Kd 5.15
G-protein coupled receptor family C group 6 member A	GPRC6A	agonist	EC50 4.40

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-23	PMDA	—	FUJIFILM TOYAMA CHEMICAL Co., Ltd.
2019-07-25	EMA	—	Advanced Accelerator Applications
1973-02-28	FDA	—	PHARMACIA AND UPJOHN

ATC classification

ATC code	Therapeutic hierarchy
B05XB01	BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › I.V. SOLUTION ADDITIVES › Amino acids
V03AF11	VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Detoxifying agents for antineoplastic treatment

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hyperammonaemic crisis	134.7
Hyperammonaemia	91.2
Haematuria	87.7
Ammonia increased	57.2
Blindness cortical	55.0
Premature baby	50.3
Foetal growth restriction	46.0
Infantile apnoea	30.8
Device related sepsis	29.4
Blood osmolarity decreased	29.3
Selective eating disorder	27.6
Status epilepticus	24.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Arginine is on its molecule page.

• Molecular formula: C₆H₁₄N₄O₂
• Molecular weight: 174.20 g/mol
• CAS number: 74-79-3
• InChIKey: ODKSFYDXXFIFQN-BYPYZUCNSA-N
• PubChem CID: 6322

N[C@@H](CCCNC(N)=N)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Arginine used for?

DrugCentral lists the following indications for Arginine: Diagnostic Test for Growth Hormone Secretion and Renal radiation exposure from Lutetium (177Lu) oxodotreotide.

How does Arginine work?

Its molecular targets in DrugCentral include NOS2 and GPRC6A (agonist).

When was Arginine first approved?

Arginine was first approved by the FDA in 1973.

What is the chemical formula of Arginine?

Arginine has the molecular formula C6H14N4O2 and a molecular weight of 174.20 g/mol.

Sources

• DrugCentral drug card 1549 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200381 — compound record and bioactivity
• PubChem CID 6322 — chemical identifiers
• DrugBank DB00125 — drug record
• FDA UNII 94ZLA3W45F — substance identity
• DailyMed: FDA labels for Arginine — current prescribing information (label search)
• UniProt P35228 (NOS2) — target protein
• UniProt Q5T6X5 (GPRC6A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.